查看文章

Statins reduce coronary and cerebrovascular events in primary and secondary prevention. More intensive statin therapy compared with moderate-intensity statin therapy decreases risk even further (1). Therefore, the 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines recommend high-intensity statin therapy in highrisk patients. This recommendation is partly on the basis of the documented safety of higher doses. However, meta-analyses have reported a slight increase in the risk of new-onset diabetes (NOD) with statin therapy over placebo; this risk increases by an additional 12% with high-intensity therapy (2).

Fasting blood glucose (FBG)> 100 mg/dl is a strong predictor of NOD; however, the incidence of NOD during statin therapy in patients with pre-diabetes (PD), which is defined as a FBG of 100 to 126 mg/dl, compared with those with normal glucose levels, has not been …